These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34027694)

  • 41. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
    Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
    Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
    Torres S; Trudeau M; Gandhi S; Warner E; Verma S; Pritchard KI; Petrella T; Hew-Shue M; Chao C; Eisen A
    Oncologist; 2018 Jul; 23(7):768-775. PubMed ID: 29371476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study.
    Bonneterre J; Prat A; Galván P; Morel P; Giard S
    Curr Med Res Opin; 2016 May; 32(5):835-9. PubMed ID: 26809116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer.
    Stein RC; Dunn JA; Bartlett JM; Campbell AF; Marshall A; Hall P; Rooshenas L; Morgan A; Poole C; Pinder SE; Cameron DA; Stallard N; Donovan JL; McCabe C; Hughes-Davies L; Makris A;
    Health Technol Assess; 2016 Feb; 20(10):xxiii-xxix, 1-201. PubMed ID: 26867046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
    Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
    Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The IHC4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020?
    Harel N; Cheema S; Williams D; Ireland-Jenkin K; Fancourt T; Dodson A; Yeo B
    Asia Pac J Clin Oncol; 2021 Aug; 17(4):368-376. PubMed ID: 33567144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer.
    Whelan T; Sawka C; Levine M; Gafni A; Reyno L; Willan A; Julian J; Dent S; Abu-Zahra H; Chouinard E; Tozer R; Pritchard K; Bodendorfer I
    J Natl Cancer Inst; 2003 Apr; 95(8):581-7. PubMed ID: 12697850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital.
    Bargallo JE; Lara F; Shaw-Dulin R; Perez-Sánchez V; Villarreal-Garza C; Maldonado-Martinez H; Mohar-Betancourt A; Yoshizawa C; Burke E; Decker T; Chao C
    J Surg Oncol; 2015 Feb; 111(2):203-7. PubMed ID: 25288020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
    Hequet D; Callens C; Gentien D; Albaud B; Mouret-Reynier MA; Dubot C; Cottu P; Huchon C; Zilberman S; Berseneff H; Foa C; Salmon R; Roulot A; Lerebours F; Salomon A; Ghali N; Morel P; Li Q; Cayre A; Guinebretière JM; Hornberger J; Penault-Llorca F; Rouzier R
    PLoS One; 2017; 12(10):e0185753. PubMed ID: 29045452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
    Jasem J; Fisher CM; Amini A; Shagisultanova E; Rabinovitch R; Borges VF; Elias A; Kabos P
    J Natl Compr Canc Netw; 2017 Apr; 15(4):494-503. PubMed ID: 28404760
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
    Markopoulos C; van de Velde C; Zarca D; Ozmen V; Masetti R
    Eur J Surg Oncol; 2017 May; 43(5):909-920. PubMed ID: 27639633
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor.
    Loibl S; Weber K; Huober J; Krappmann K; Marmé F; Schem C; Engels K; Pfitzner BM; Kümmel S; Furlanetto J; Hartmann A; Darb-Esfahani S; Müller V; Staebler A; von Minckwitz G; Kronenwett R; Denkert C
    Clin Cancer Res; 2018 Jul; 24(14):3358-3365. PubMed ID: 29618617
    [No Abstract]   [Full Text] [Related]  

  • 56. Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature.
    Drukker CA; van den Hout HC; Sonke GS; Brain E; Bonnefoi H; Cardoso F; Goldhirsch A; Harbeck N; Honkoop AH; Koornstra RH; van Laarhoven HW; Portielje JE; Schneeweiss A; Smorenburg CH; Stouthard J; Linn SC; Schmidt MK
    Eur J Cancer; 2014 Apr; 50(6):1045-54. PubMed ID: 24529927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer.
    Zeng Y; Gao W; Lin L; Chen X; Shen K
    J Geriatr Oncol; 2020 Jun; 11(5):843-849. PubMed ID: 31704037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients.
    Assi HI; Alameh IA; Khoury J; Abdul Halim N; El Karak F; Farhat F; Berro J; Sbaity E; Charafeddine M; Tfayli A; Salem Z; El Saghir N
    J Oncol; 2020; 2020():9238084. PubMed ID: 33312202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.
    Zeng Y; Li Q; Qin T; Li S; Jin L; Wu J; Chen K; Deng H; Rao N; Liu Q; Su F; Jia W; Yao H
    Anticancer Res; 2017 Aug; 37(8):4539-4547. PubMed ID: 28739750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.
    Tsai M; Lo S; Audeh W; Qamar R; Budway R; Levine E; Whitworth P; Mavromatis B; Zon R; Oldham D; Untch S; Treece T; Blumencranz L; Soliman H
    JAMA Oncol; 2018 Jan; 4(1):e173470. PubMed ID: 29075751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.